Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | RORC | P51449 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.60 |
| ▸ | SNCA | P37840 | 1/20 | 0.60 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064051 | 1.00 | TRPV1 (0.73) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL7513604 | 0.93 | TRPV1 (0.83) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL900928 | 0.87 | DEGS1 (0.75) | NPC1RAB9AMEN1LMNAKMT2A | |
| SCHEMBL8420639 | 0.87 | DEGS1 (0.75) | NPC1RAB9AMEN1LMNAKMT2A | |
| SCHEMBL899585 | 0.87 | DEGS1 (0.75) | NPC1RAB9AMEN1LMNAKMT2A | |
| SCHEMBL674439 | 0.86 | HDAC6 (0.82) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL11730950 | 0.86 | NPC1 (0.77) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL18031166 | 0.85 | EPHX2 (0.85) | TRPV1NPC1RAB9ARORCMAPT | |
| SCHEMBL95224 | 0.84 | TRPV1 (0.71) | TRPV1PTGS1NPC1RAB9ARORC | |
| SCHEMBL22721382 | 0.84 | PTGS1 (0.76) | TRPV1PTGS1NPC1RAB9ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| CN-101917845-A | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD | 2010-12-15 | — | — | CN | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
| EP-2222160-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | Pharmaxis Ltd. (AU) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1468680-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-0585366-B1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | UNIV VIRGINIA COMMONWEALTH (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1236711-B1 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | UNIV VIRGINIA COMMONWEALTH (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1236711-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0585366-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5290803-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | THE CENTER OF INNOVATIVE TECHNOLOGY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5250701-A | 2-(Phthalomidomethylphenoxyalkanoic acid or ester; wound healing agents; antiischemic agents; blood storage; antidepressants; Alzheimer's disease; schizophrenia | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5248785-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| WO-1992020335-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0471811-A4 | ALLOSTERIC HEMOGLOBIN MODIFIERS | — | 1992-11-25 | — | — | EP | disclosed |
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | disclosed |
| EP-0471811-A1 | ALLOSTERIC HEMOGLOBIN MODIFIERS. | INNOVATIVE TECH CENTER (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5049695-A | Substituted diphenyl carbamates | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1991-09-17 | — | — | US | disclosed |
| WO-1991012235-A1 | ALLOSTERIC HEMOGLOBIN MODIFIERS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | TRPV1 629/4885PTGS1 449/4885NPC1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.